Ziel
The mission of EpiPredict is to train a multidisciplinary cohort of young researchers in a new approach to fully exploit the epigenetics of complex diseases. The 12 early-stage researchers (ESRs) will focus on a narrowly defined case, Tamoxifen-induced resistance in Estrogen Receptor positive (ER+) breast cancer, considering five resistance interacting pathways. Given the frequent Tamoxifen treatment failure, resistance prevention and reversal is an urgent clinical problem that is central in EpiPredict. The EpiPredict intersectorial training programme employs a timely systems medicine approach combining next-generation systematic epigenetic, gene/protein profiling with innovative gene-specific epigenetic interference technologies for iterative computational modelling. Together the ESRs will identify key epigenetic changes underlying Tamoxifen induced resistance. This will provide an important step towards diagnostic markers/tools to predict treatment outcome and response monitoring setting the scene for breast cancer personalized medicine. The fellows will be trained by experts from 6 academic and 2 non-academic beneficiaries and 7 partner organizations (1 academic, 6 non-academic including industrial/socio-public parties) and 5 visiting scientists, from fields ranging from epigenetics to both computation and medicine. Strong involvement of the private sector ensures exploitation of EpiPredict achievements and exposure of the ESRs to an entrepreneurial mindset.
The cohort of supradisciplinary researchers represents a new generation of research leaders equipped to address complex diseases whilst taking personalized patient aspects into consideration. They will be equipped to compete successfully and succeed in their personal careers. EpiPredict will boost academia and pharma/biotech environments, providing extra impulses to drive European translational science, systems medicine, pharmaceutical industry, and Medical ICT offering ample job opportunities.
Wissenschaftliches Gebiet
- /Naturwissenschaften/Biowissenschaften/Genetik und Vererbung/DNS
- /Naturwissenschaften/Biowissenschaften/Biochemie/Biomoleküle/Proteine
- /Medizin- und Gesundheitswissenschaften/Grundlagenmedizin/Pharmakologie und Pharmazie/Arzneimittelresistenz
- /Medizin- und Gesundheitswissenschaften/Klinische Medizin/Onkologie/Krebs/Brustkrebs
- /Naturwissenschaften/Biowissenschaften/Genetik und Vererbung/Epigenetik
Programm/Programme
Aufforderung zur Vorschlagseinreichung
H2020-MSCA-ITN-2014
Andere Projekte für diesen Aufruf anzeigen
Finanzierungsplan
MSCA-ITN-ETN - European Training Networks
Koordinator
1012WX Amsterdam
Niederlande
Beteiligte (7)
SW7 2AZ London
69120 Heidelberg
20126 Milano
9713 GZ Groningen
6726 Szeged
12489 Berlin
Beteiligung beendet
CR5 2NR Coulsdon Surrey
Partner (7)
2333 CH Leiden
41288 Goeteborg
8020 Graz
Budapest
Amsterdam
1097 AZ Amsterdam
8092 Zuerich